Full Moon August 2025: When To See The ‘Sturgeon Moon' Rise
A full moon, known as a Sturgeon moon, rises over South Shields Lighthouse in the North East Of England. (Photo by Owen Humphreys/PA Images via Getty Images) PA Images via Getty Images
The sturgeon moon will turn full at 3:56 a.m. EDT on Saturday, Aug. 9. It will look full the night before, and the night after, it's officially 100%-lit by the sun. The best time to watch it rise in North America will be at moonrise during dusk on Friday, Aug. 8, though the west coast will get a second chance on Saturday, Aug. 9.
According to EarthSky, August's full moon is known as the sturgeon, green corn and grain moon. Cultural and seasonal names for the full moon vary hugely across the world.
A full moon always looks at its best when it first appears above the eastern horizon during dusk. The sight is at its best when the moon rises shortly after sunset, which it does this month in North America, with the sturgeon moon rising about the same time as the sun goes down. From the west coast, it rises shortly after sunset the following evening.
To see the full sturgeon moon at its best, find an elevated location, an open field or an east-facing coastline with a clear view of the eastern horizon. The naked eye is fine, but binoculars or a small telescope will offer a closer look.
To find the best time to see it appear from where you are, consult a moonrise calculator. Here are some sample times : New York: sunset at 8:04 p.m. EDT, moonrise at 8:03 p.m. EDT on Friday, Aug. 8 and sunset at 8:03 p.m. EDT, moonrise at 8:32 p.m. EDT on Saturday, Aug. 9.
Los Angeles: sunset at 7:48 p.m. PDT, moonrise at 7:48 p.m. PDT on Friday, Aug. 8 and sunset at 7:47 p.m. PDT, moonrise at 8:21 p.m. PDT on Saturday, Aug. 9.
London: sunset at 8:37 p.m. BST, moonrise at 8:40 p.m. BST on Friday, Aug. 8 and sunset at 8:36 p.m. BST, moonrise at 8:58 p.m. BST on Saturday, Aug. 9. Next Month's Total Lunar Eclipse
Next month's full moon — September's corn moon — will be a total lunar eclipse on Sunday, Sept. 8. Visible from parts of Asia, Australia and the Pacific, the event will see the moon move through Earth's shadow in space in stages. The penumbral and partial phases (as the full moon moves through Earth's fuzzy outer shadow, the penumbra , and into its dark umbra ) will precede totality when the lunar surface turns dark and red. Totality will last for 82 minutes and will be followed by partial and penumbral phases as the moon exits Earth's shadow. The entire event will last five hours and 27 minutes. No part of the eclipse will be seen from North or South America. It will be the third and final full summer moon in the Northern Hemisphere and winter in the Southern Hemisphere.
ONTARIO, CANADA - MARCH 14: A blood moon lights up the sky during the total lunar eclipse on March 14, 2025 in Ontario, Canada. (Photo by Chen Shaojin/VCG via Getty Images) VCG via Getty Images
The next total solar eclipse on Earth will occur just over a year after this month's full sturgeon moon. On Aug. 12, 2026, a path of totality will travel through eastern Greenland, western Iceland and northern Spain, where a dramatic totality of about two minutes will be experienced. The next total solar eclipse in the contiguous U.S. will occur on Aug. 22, 2044. Further Reading Forbes See Two 'Blood Moons,' Three 'Supermoons' And The Biggest Full Moon Since 2019: The Moon In 2025 By Jamie Carter Forbes Perseid Meteor Shower 2025: Why You Need To Change Your Plans By Jamie Carter Forbes These Are The Meteor Showers Not To Miss In 2025 — By An Expert By Jamie Carter
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
FDA approves SetPoint's neuroimmune modulation device for RA treatment
The US Food and Drug Administration (FDA) has approved SetPoint Medical's implantable neuroimmune modulation device, SetPoint System, to treat moderate-to-severe rheumatoid arthritis (RA) in adults. The system is designed for individuals who are inadequately managed by or intolerant to current RA therapies such as biological and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs). The system is said to activate the body's natural anti-inflammatory and immune-restorative pathways by delivering electrical stimulation to the vagus nerve once a day. The neurostimulation therapy can potentially provide an alternative treatment without immune-compromising risks. The FDA approval was based on the outcomes of the RESET-RA study, a 242-patient double-blind, randomised, sham-controlled trial, which showed the system's efficacy and safety in this patient group. Patients tolerated the device placement procedure and the stimulation therapy well, with a low incidence of related serious adverse events at 1.7%. SetPoint Medical CEO Murthy Simhambhatla said: 'The approval of the SetPoint System, the first-in-class neuroimmune modulation platform, represents a transformative milestone in the management of autoimmune diseases. 'We are committed to improving the health of people living with RA, and look forward to working with providers and payers to make our innovative therapy accessible to their patients. We plan to introduce the SetPoint System in targeted US cities this year, followed by expansion across the country starting in early 2026.' SetPoint Medical is also exploring the use of its neuroimmune modulation platform for other autoimmune diseases such as multiple sclerosis (MS) and Crohn's disease. In March 2024, the company's neuroimmune modulation device secured a breakthrough device designation to treat relapsing-remitting MS. "FDA approves SetPoint's neuroimmune modulation device for RA treatment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
41 minutes ago
- Yahoo
NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer
CALABASAS, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi-phase 2 clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, was featured on Yahoo Finance's Trader Talk with Kenny Polcari in a podcast episode titled 'AI and Biotech Take on Brain Cancer.' As Trader Talk describes it: 'When a biotech startup lands in a major index just months after its IPO, investors take notice. In this episode of Trader Talk, Kenny Polcari speaks with Amir Heshmatpour, executive chairman and president of NeOnc Technologies (Nasdaq: NTHI), about how the company defied a tough market to go public, secure a $50 million partnership in the Middle East, and join the Russell Microcap Index. Heshmatpour explains NeOnc's focus on intranasal drug delivery for brain cancer, the significance of its partnership with USC's medical school, and how global clinical trials are expanding the company's reach. The conversation also includes how AI and quantum computing could transform the biotech industry. It's a rare behind-the-scenes look at how a small-cap biotech is executing on a global stage.' You can tune in to the episode on Apple Podcasts, Spotify, YouTube, or wherever you listen to your podcasts. ABOUT NEONC TECHNOLOGIES HOLDINGS, Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company's NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc's NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions. For more about NeOnc and its pioneering technology, visit Important Cautions Regarding Forward Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'should,' 'intend,' 'expect,' 'plan,' 'budget,' 'forecast,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'potential,' 'continue,' 'evaluating,' or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information. Examples of forward-looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated. The 'Risk Factors' section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds. We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations. 'NEO100' and NEO '212' are registered trademarks of NeOnc Technologies Holdings, Inc. Company Contact:info@ Investor Contact:James CarbonaraHayden IR(646)-755-7412James@
Wall Street Journal
44 minutes ago
- Wall Street Journal
Does Artificial Intelligence Belong In Schools?
Regarding 'A Teachers Union's Dangerous Embrace of AI' (op-ed, Aug. 1), I agree with Rebecca Zimmerman's prescription for helping students flourish—focusing on mental health initiatives, cellphone bans during the school day and science-based reading curriculums—all priorities the American Federation of Teachers champions. Where we disagree is over the effect of artificial intelligence in education, specifically Ms. Zimmerman's assertion that AI is 'another fad that will distract teachers.' AI already has an inescapable influence on nearly every part of our lives. I believe, for better or worse, that it will be as transcendent as the printing press.
